EGEN, Inc., is a clinical stage biopharmaceutical company focused on developing nucleic acid-based therapeutics for cancer and other difficult to treat diseases using proprietary nanoparticle delivery systems. The Company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes therapeutic genes, inhibitory RNA (RNAi), messenger RNA (mRNA), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking.

EGEN Clinical Trials

EGEN-001 utilizing EGEN's proprietary TheraPlas technology is being tested in the following clinical trials:

Ovarian CancerRibbon

  Phase II - EGEN-001

  Phase I  - EGEN-001 + LipoDox

Latest News

June 6, 2013
EGEN, Inc. Announces Positive Outcome of Study in a Rat Model of Pulmonary Arterial Hypertension (PAH) Using its Proprietary RNAi Delivery Technology

March 19, 2013
EGEN, Inc. Announces a Phase I Clinical Trial for Advanced Ovarian Cancer


A proprietary delivery technology that creates safe and effective gene-based biopharmaceuticals... More


A new class of proprietary carriers that deliver siRNAs and shRNAs to regulate protein expression... More

Egen Pipeline